EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2

Zhiyuan Feng, Fangyuan Zhang iD, Aoming Jin, Xinchen Li, Yimeng Li, Qi Chu, Jing Xue, Aichun Cheng, Jinxi Lin, Hao Li, Xia Meng, Yongjun Wang und 1 weitere

Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 625-633

DOI: 10.1111/dom.70243 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.10.2025. Verfasst von Zhiyuan Feng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Metabolic Syndrome, Ischemic Attack, Transient, Platelet Aggregation Inhibitors, Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Beijing Municipal Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the relationship between metabolic syndrome and the efficacy and safety of genotype‐guided dual antiplatelet therapy (DAPT) in the CHANCE‐2 trial. Materials and methods This post hoc study used data from the CHANCE‐2 trial. Patients with minor stroke or TIA who carried the CYP2C19 loss‐of‐function (LOF) allele were randomized to receive ticagrelor‐aspirin (TIC‐ASA) or clopidogrel‐aspirin (CLO‐ASA). The primary efficacy outcome was stroke recurrence within 90 days. The primary safety outcome was severe or moderate bleeding within 90 days. We classified patients into metabolic syndrome (MetS) and non‐metabolic syndrome (non‐MetS) groups. Differences in the outcome during 90‐days follow‐up period were assessed using the Cox proportional hazards model.

Results

Among 5652 patients, 3305 were non‐MetS and 2347 were MetS. Compared with CLO‐ASA, TIC‐ASA significantly reduced the risk of stroke recurrence within 90 days among patients with MetS (6.44% vs. 9.90%; HR 0.64, 95% CI 0.48–0.85; p < 0.01); this benefit was not seen in non‐MetS (6.03% vs. 5.96%; HR 1.01, 95% CI 0.77–1.34; p = 0.93), with a significant interaction effect ( p for interaction = 0.03). Moreover, a linear trend was observed ( p for trend = 0.04), indicating metabolic health status may modify the efficacy of genotype‐guided DAPT in a dose‐dependent manner. No significant difference was observed in severe or moderate bleeding events by metabolic syndrome (MetS: 0.42% vs. 0.35%, non‐MetS: 0.25% vs. 0.36%; p for interaction = 0.55).

Conclusions

Among CYP2C19 LOF carriers with minor stroke or TIA, patients with MetS received more clinical benefit from TIC‐ASA versus CLO‐ASA compared to those with non‐MetS. Registry: ClinicalTrials.gov , TRN: NCT04078737.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeIschemic Attack, TransientPlatelet Aggregation InhibitorsStrokeDual Anti-Platelet TherapyHumansFemaleMaleCytochrome P-450 CYP2C19Middle AgedAgedClopidogrelAspirinGenotypeTicagrelorTreatment OutcomeRecurrenceDrug Therapy, Combination

Stichwörter der Autor:innen

dual antiplatelet therapymetabolic syndromeminor stroketransient ischemic attack

Substanzen

Platelet Aggregation InhibitorsCytochrome P-450 CYP2C19ClopidogrelAspirinCYP2C19 protein, humanTicagrelor

Autor:innen und Institutionen

  • Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • China National Clinical Research Center for Neurological Diseases, Beijing, China.
  • Institutes of Brain Science, Wannan Medical College, Wuhu, China.
  • Department of Neurology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China.

ORCID-Profile: Fangyuan Zhang, Jie Xu

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Beijing Municipal Science and Technology Project
  • Beijing Hospitals Authority Clinical Medicine Development of special funding support

Zitieren

APA

Feng, Z., Zhang, F., Jin, A., Li, X., Li, Y., Chu, Q., Xue, J., Cheng, A., Lin, J., Li, H., Meng, X., Wang, Y., & Xu, J. (2026). Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2. Diabetes, Obesity and Metabolism, 28(1), 625-633. https://doi.org/10.1111/dom.70243

Vancouver

Feng Z, Zhang F, Jin A, Li X, Li Y, Chu Q, et al. Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2. Diabetes, Obesity and Metabolism. 2026;28(1):625-633. doi:10.1111/dom.70243

BibTeX
@article{Feng2026,
  author = {Feng, Zhiyuan and Zhang, Fangyuan and Jin, Aoming and Li, Xinchen and Li, Yimeng and Chu, Qi and Xue, Jing and Cheng, Aichun and Lin, Jinxi and Li, Hao and Meng, Xia and Wang, Yongjun and Xu, Jie},
  title = {Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {1},
  pages = {625--633},
  doi = {10.1111/dom.70243}
}
Kostenlos starten →